dr. camidge on the keynote-024 trial in nsclc
Published 6 years ago • 165 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
0:30
copy of dr. camidge on the keynote-024 trial in nsclc
-
3:31
the keynote-024 precedent for advanced-nsclc treatment
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
1:37
dr. camidge on the alex trial in patients with alk nsclc
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
0:36
dr. camidge on the fda approval of pembrolizumab for squamous nsclc
-
1:18
dr. reck on the safety of pembrolizumab in keynote-024 in metastatic nsclc
-
1:51
dr. camidge on biomarker combinations in nsclc
-
1:00
dr. camidge on phase i study with azd9291 in nsclc
-
1:52
dr. camidge on optimal therapy in egfr nsclc
-
2:25
dr. gadgeel on updated keynote-189 data in nsclc
-
1:54
dr. gainor on the pacific-2 trial in stage iii nsclc
-
4:47
benefit of pembrolizumab in nsclc: the keynote trials
-
4:18
dr. ross camidge on the ever changing world of clinical cancer research
-
8:44
upfront immunotherapy for pd-l1 nsclc
-
1:20
pembro continues to demonstrate os benefit in first-line nsclc: keynote-024 update
-
1:51
dr. camidge discusses treatment of patients with alk nsclc
-
3:04
keynote-024 update: pembrolizumab vs platinum-based chemotherapy in nsclc
-
2:30
dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc